Clinical trials: Severe Mental Disorders
Major Depression
Study of Psilocybin Under Anesthesia Controlled by EEG
Major depressive disorder (MDD) affects millions of Americans and remains difficult to treat. Psilocybin, a psychedelic compound, has shown promise for reducing depression symptoms, but a key challenge in psychedelic research is…
- Trial name
- SPACE (NCT07479550)
- Testing
- Psilocybin (Usona Institute), Propofol
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Obsessive-Compulsive Disorder
Deep Brain Stimulation for Severe Obsessive Compulsive Disorder
The overarching aim is to compare the effects of ventral capsule/ventral striatum (VC/VS) and subthalamic nucleus (STN) deep brain stimulation (DBS) in the same participants.
- Trial name
- NCT02655926
- Testing
- Deep Brain Stimulation
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- University College, London
Major Depressive Disorder, Irritability
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
To explore the anti-impulsive and anti-aggressive properties of brexpiprazole in a naturalistic setting of depressed patients with irritability.
- Trial name
- NCT01942785
- Testing
- Brexpiprazole
- Where
- 15 sites in United States
- Volunteers
- 55 people
- Sponsor
- H. Lundbeck A/S
Major Depression
Efficacy and Safety of Homeopathy for Moderate Depression (Acute Phase)
To assess the two components of individualized homeopathic treatment for acute depression, i.e., to investigate the specific effect of individualized Q-potencies versus placebo and to investigate the effect of different…
- Trial name
- DEP-HOM (NCT01178255)
- Testing
- homeopathic q-potencies, homeopathic case history taking type I, homeopathic case history type II
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Charite University, Berlin, Germany
Depression, Bipolar Disorder
Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder
The primary outcome of this study is to determine if predictors of response can select a population of patients with MDD that is effectively treatable by augmentation with ziprasidone.
- Trial name
- NCT01168674
- Testing
- ziprasidone, Sugar pill
- Volunteers
- 49 people
- Sponsor
- Tufts Medical Center
Major Depression, Functional Dyspepsia
The Brain-Heart-Gut Connection
Major Depressive Disorder (MDD) often co-occurs with cardiovascular and gastrointestinal symptoms, highlighting the importance of the brain-heart-gut connection in developing comprehensive treatments.
- Conditions
- Major Depression, Functional Dyspepsia, Autonomous Dysfunction
- Trial name
- BHG-CONNECT (NCT06748274)
- Testing
- Transcranial Magnetic Stimulation (TMS), High-definition transcranial direct current stimulation (HD-tDCS)
- Where
- Switzerland
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Bern
Major Depressive Disorder
A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients
The purpose of this study is to compare the efficacy and safety of duloxetine 60 mg once daily to placebo on depression in elderly patients (greater than or equal to 65 years of age).
- Trial name
- NCT00406848
- Testing
- duloxetine hydrochloride
- Where
- 33 sites in United States, France and 2 more
- Volunteers
- 370 people
- Sponsor
- Eli Lilly and Company
Depression - Major Depressive Disorder, Depression Disorders
Racial Disparities in Antidepressant Treatment After a Psychiatric Consultation
Patients from black, indigenous, and people of color (BIPOC) communities are reported to have lower rates of antidepressant adherence and response. The investigators have a limited understanding of why this disparity exists.
- Trial name
- RITA-PC (NCT06799078)
- Testing
- Observation while participants receive treatment by their primary care provider
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder, Overweight
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach
This project aims to evaluate whether a dose-response relationship exists between dose of polyunsaturated fatty acids (PUFA), delivered as eicosapentaenoic acid (EPA), and change in markers of inflammation, and whether these…
- Conditions
- Major Depressive Disorder, Overweight, Inflammation
- Trial name
- NCT02553915
- Testing
- EPA 1 g/day, EPA 2 g/day, EPA 4 g/day
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Sumor as Adjuvant Therapy in Treatment-resistant Major Depression
Sumor is a food supplement that combines the main coenzymes of the S-Adenosyl methionine (SAMe) cycle, namely vitamins B6, B12 and folate, with SAMe and betaine.
- Trial name
- SUSCA (NCT04832178)
- Testing
- SUMOR
- Where
- Italy
- Volunteers
- 102 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Schizophrenia, Major Depressive Disorder
Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals
This study aims to screen and validate multi-scale bio-markers for early diagnosis and medication monitoring for early schizophrenia, including the genetic, neurobiochemistry, neuroimaging and eletrophysiological measures.
- Conditions
- Schizophrenia, Major Depressive Disorder, Anxiety Disorders
- Trial name
- NCT03790085
- Testing
- Risperidone, Olanzapine, Aripiprazole
- Where
- China
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University General Hospital
Depression - Major Depressive Disorder, Transcranial Alternating Current Stimulation
Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder
The purpose of this research study is to investigate a closed-loop transcranial alternating current stimulation (tACS) device to evaluate its ability to reduce symptoms of major depressive disorder
- Trial name
- NCT07282678
- Testing
- Closed-loop tACS
- Where
- United States
- Volunteers
- 214 people
- Sponsor
- Pulvinar Neuro, LLC
Major Depressive Disorder
A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy in patients with major depressive disorder.
- Trial name
- NCT02395978
- Testing
- PDC-1421 Capsule
- Where
- 5 sites in United States, Taiwan
- Volunteers
- 72 people
- Sponsor
- BioLite, Inc.
Depression / Major Depressive Disorder
Adjunctive Probiotic Therapy in Major Depressive Disorder (ProMOOD)
A double-blind, randomized controlled trial (RCT) aimed at evaluating the efficacy of probiotic supplementation in patients undergoing concurrent antidepressant therapy.
- Trial name
- ProMOOD (NCT07786285)
- Testing
- OMNi-BiOTiC® STRESS Repair
- Where
- Slovenia
- Volunteers
- 200 people
- Sponsor
- University Maribor
Stress Disorders, Post-Traumatic, Depressive Disorder, Major
The Effect of Traumatic Childbirth on the Incidence of PTSD and Other Major Postpartum Psychopathology
Determination of incidence and prevalence of PTSD and other types of psychopathology (such as anxiety and affective disorders) after traumatic birth experiences and elucidation of salient risk factors in the local population…
- Trial name
- NCT02370576
- Testing
- rating scale application
- Where
- Israel
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Major Depressive Disorder
Tracking Response to Antidepressants in Advance of Investigational Trials
TRAIT is an open-label observational study to evaluate treatment response to selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs) among individuals meeting criteria for Major…
- Trial name
- TRAIT (NCT04748276)
- Testing
- FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Adams Clinical
Major Depressive Disorder (MDD)
Effectiveness of MST Versus ECT for Major Depressive Episode
Despite advancements in Magnetic Seizure Therapy (MST) and Electroconvulsive Therapy (ECT) for Major Depressive Disorder (MDD), there remains a need for further research to replicate clinical outcomes and understand the…
- Trial name
- NCT06409325
- Testing
- MST, ECT
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Shanghai Mental Health Center
Major Depressive Disorder, Substance Use Disorder
Defining Neurobiological Links Between Substance Use and Mental Illness
Background: Nicotine dependence leads to about 480,000 deaths every year in the United States. People with major depressive disorder (MDD) are twice as likely to use nicotine compared to the general population.
- Conditions
- Major Depressive Disorder, Substance Use Disorder, Normal Physiology
- Trial name
- NCT05538910
- Testing
- Nicotine Patch
- Where
- United States
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Generalized Anxiety Disorder, Social Anxiety Disorder
Floatation-REST (Reduced Environmental Stimulation Therapy) for Anxiety and Depression
This early-stage trial aims to examine the feasibility, tolerability, and safety of Floatation-REST (Reduced Environmental Stimulation Therapy) or an active comparison condition in 75 participants with clinical anxiety and…
- Conditions
- Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia
- Trial name
- NCT03899090
- Testing
- Float pool, Float chair
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Laureate Institute for Brain Research, Inc.
Major Depressive Disorder (MDD), History of Childhood Sexual Abuse (CSA)
An Investigation of Early Life Stress and Depression
The purpose of this study is to investigate brain pathways within adult females (with a history of CSA that occurred between the ages of 5-14) with and without a current diagnosis of major depressive disorder (MDD).
- Trial name
- NCT01701258
- Testing
- Amisulpride
- Where
- 2 sites in United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.